Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium

Rudebeck, Mattias, Scott, Ciaran, Rhodes, Nicholas P ORCID: 0000-0002-5173-7032, van Kan, Christa, Olsson, Birgitta, Al-sbou, Mohammed, Hall, Anthony K, Sireau, Nicolas and Ranganath, Lakshminarayan R (2021) Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium. ORPHANET JOURNAL OF RARE DISEASES, 16 (1). 510-.

Text XX052 Rudebeck 2021.pdf - Published version Download (1MB) | Preview

Abstract

New opportunities have arisen for development of therapies for rare diseases with the increased focus and progress in the field. However, standardised framework integrating individual initiatives has not been formed. We present lessons learned and best practice from a collaborative success case in developing a treatment for a rare genetic disease. Our unique consortium model incorporated several of the identified developments under one project, DevelopAKUre, truly bringing together academia, industry and patient organisations in clinical drug development. We found that the equal partnership between all parties in our consortium was a key success factor creating a momentum based on a strong organisational culture where all partners had high engagement and taking ownership of the entire programme. With an agreed mutual objective, this provided synergies through connecting the strengths of the individual parties. Another key success factor was the central role of the patient organisation within the management team, and their unique study participants' advocacy role securing the understanding and meeting the needs of the clinical study participants in real-time. This resulted in an accelerated enrolment into the clinical studies with a high retention rate allowing for delivery of the programme with significantly improved timelines. Our project was partly funded through an external EU research grant, enabling our model with equal partnership. Further attention within the community should be given to establishing a functional framework where sustainable funding and risk sharing between private and public organisations allow for our model to be replicated.

Item Type:	Article
Uncontrolled Keywords:	Rare diseases, Drug development, Alkaptonuria, AKU, DevelopAKUre, Best practice
Divisions:	Faculty of Science and Engineering > School of Physical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	10 Jan 2022 14:32
Last Modified:	18 Jan 2023 21:18
DOI:	10.1186/s13023-021-02137-0
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3146131